0001209191-20-059528.txt : 20201119 0001209191-20-059528.hdr.sgml : 20201119 20201119190119 ACCESSION NUMBER: 0001209191-20-059528 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200601 FILED AS OF DATE: 20201119 DATE AS OF CHANGE: 20201119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graham G. Walmsley CENTRAL INDEX KEY: 0001777517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39712 FILM NUMBER: 201330035 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Olema Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001750284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 300409740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 651-3316 MAIL ADDRESS: STREET 1: 512 2ND STREET, 4TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94107 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-01 0 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001777517 Graham G. Walmsley C/O LOGOS GLOBAL MANAGEMENT LP 1 LETTERMAN DRIVE, BLDG. D, STE D3-700 SAN FRANCISCO CA 94129 1 0 0 0 Series B Convertible Preferred Stock 2020-06-01 4 P 0 339578 4.7117 A Common Stock 339578 339578 I See Footnote Series C Convertible Preferred Stock 2020-09-30 4 P 0 1183114 11.0623 A Common Stock 1183114 1183114 I See Footnote Stock Option (Right to Buy) 19.00 2020-11-18 4 A 0 21520 0.00 A 2030-11-17 Common Stock 21520 21520 D Stock Option (Right to Buy) 19.00 2020-11-18 4 A 0 21520 0.00 A 2030-11-17 Common Stock 21520 21520 D Stock Option (Right to Buy) 19.00 2020-11-18 4 A 0 21520 0.00 A 2030-11-17 Common Stock 21520 21520 D The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunies GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares are held by Logos Opportunities Fund II, L.P. ("Logos Fund II"). Logos GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. /s/ John B. Moriarty, Jr., Attorney-in-Fact 2020-11-19